Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Stereotaxis, Inc. (OTC: STXS).

Full DD Report for STXS

You must become a subscriber to view this report.


Recent News from (OTC: STXS)

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2018 Results - Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2018 Earnings Conference Call August 07, 2018, 10:00 ET Executives David Fischel - CEO & Chairman Martin Stammer - CFO Analysts Presentation Operator Good morning. Thank you for joining us for the Stereotaxis Second Quarter 2018 Earnin...
Source: SeekingAlpha
Date: August, 07 2018 16:46
Stereotaxis Reports 2018 Second Quarter Financial Results
Progress on strategic internal innovation and external collaborations Continued growth in recurring revenue Positive cash flow from operations Reaffirming 2018 expectations Conference call today at 10:00 a.m. Eastern Time ST. LOUIS, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc...
Source: GlobeNewswire
Date: August, 07 2018 09:00
Stereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
ST. LOUIS, July 31, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, Augu...
Source: GlobeNewswire
Date: July, 31 2018 09:00
Stereotaxis and Johnson & Johnson's Biosense Webster Extend Development Alliance and Supply Agreement
ST. LOUIS, June 25, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with J...
Source: GlobeNewswire
Date: June, 25 2018 08:30
Stereotaxis Announces Changes to its Board of Directors
ST. LOUIS, June 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr. Levin is the Director of Research at Ar...
Source: GlobeNewswire
Date: June, 04 2018 09:00
Stereotaxis to Present at 8th Annual LD Micro Invitational
ST. LOUIS, May 22, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 8th Annual LD M...
Source: GlobeNewswire
Date: May, 22 2018 09:00
Stereotaxis' (STXS) CEO David Fischel on Q1 2018 Results - Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2018 Earnings Conference Call May 14, 2018 10:00 AM ET Executives David Fischel - Chairman and CEO Martin Stammer - CFO Analysts John Morganelli - Private Investor Joe Hurley - Chi Rho Financial Presentation Operator Good morning. Thank...
Source: SeekingAlpha
Date: May, 14 2018 13:20
Stereotaxis Reports 2018 First Quarter Financial Results
3% year-over-year growth in recurring revenue Continued progress on strategic innovation initiatives; collaboration with Acutus Medical Increasing quantity and quality of peer-reviewed clinical validation Strong financial position to reach profitability without the need for additional ...
Source: GlobeNewswire
Date: May, 14 2018 09:00
Stereotaxis to Highlight Unique Advantages of Robotic Cardiac Ablation at Heart Rhythm 2018
ST. LOUIS, May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at the Boston Conv...
Source: GlobeNewswire
Date: May, 04 2018 09:05
Stereotaxis to Report First Quarter 2018 Financial Results on May 14, 2018
ST. LOUIS, May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14...
Source: GlobeNewswire
Date: May, 04 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.401.3651.411.259,305
2018-12-131.251.401.421.2515,630
2018-12-121.241.301.311.2310,100
2018-12-111.29651.251.341.2333,815
2018-12-101.221.311.371.2119,650

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-144,7709,30551.2628Short
2018-12-135,81615,63037.2105Short
2018-12-129,35010,10092.5743Short
2018-12-1115,38933,81545.5094Short
2018-12-1011,71019,65059.5929Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on STXS.


About Stereotaxis, Inc. (OTC: STXS)

Logo for Stereotaxis, Inc. (OTC: STXS)

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab.

 

Contact Information

 

 

Current Management

  • David Fischel / CEO
  • Martin C. Stammer / CFO, IR
  • Paul Brathwaite / VP, R amp D
  • Karen Duros / General Counsel
  • David Fischel / Chairman
  • David W. Benfer / Independent Director, Nominating Committee Member
  • Joseph Kiani /
  • Arun Menawat /
  • Robert J Messey / Independent Director, Audit Committee Member, Compensation Committee Member
  • Fred A Middleton / Independent Director, Compensation Committee Member

Current Share Structure

  • Market Cap: $16,361,339 - 03/16/2018
  • Authorized: 300,000,000 - 03/16/2018
  • Issue and Outstanding: 23,076,642 - 03/16/2018

 


Recent Filings from (OTC: STXS)

Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 20 2018

 

 


Daily Technical Chart for (OTC: STXS)

Daily Technical Chart for (OTC: STXS)


Stay tuned for daily updates and more on (OTC: STXS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: STXS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in STXS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of STXS and does not buy, sell, or trade any shares of STXS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/